Raafat Issa, MD
Internal Medicine · Saint Clair Shores, MINPI 1750497483
Payments from drug & device makers
Across 421 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$1K
- Novo Nordisk$921
- AstraZeneca$827
- Pfizer$826
- Lilly USA, LLC$526
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,904100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $2,273 |
| AbbVie | 35 | $1,183 |
| Novo Nordisk | 35 | $921 |
| AstraZeneca | 17 | $827 |
| Pfizer | 43 | $826 |
| Lilly USA, LLC | 27 | $526 |
| Abbott | 11 | $517 |
| Amgen(2 entities) | 16 | $449 |
| Teva Pharmaceuticals USA, Inc. | 17 | $442 |
| Acadia Pharmaceuticals Inc | 12 | $224 |
| Otsuka America Pharmaceutical, Inc. | 10 | $213 |
| Boehringer Ingelheim | 11 | $202 |
| Neurocrine Biosciences, Inc. | 5 | $192 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| Exact Sciences | 6 | $114 |
| Johnson & Johnson | 6 | $100 |
| Lundbeck LLC | 4 | $83 |
| Bayer | 4 | $82 |
| Verona Pharma, Inc. | 5 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Kowa Pharmaceuticals America, Inc. | 5 | $60 |
| Merck | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Bausch Health US, LLC | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Boston Scientific | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Inari Medical, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$619
- TRELEGY ELLIPTA$589
- UBRELVY$476
- BREZTRI$357
- Ozempic$347
- AIRSUPRA$244
- AREXVY$243
- Repatha$238
- FreeStyle Libre$138
- Tresiba$125
- EUCRISA$125
- Austedo XR$119
- DUPIXENT$118
- INGREZZA$110
How this compares
$9,904 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $175,854 |
| JardianceEmpagliflozin | 144 | $82,007 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $59,802 |
| SantylCollagenase Clostridium Hist. | 84 | $57,710 |
| XareltoRivaroxaban | 87 | $51,670 |
| MounjaroTirzepatide | 39 | $49,625 |
| FarxigaDapagliflozin Propanediol | 82 | $29,540 |
| OzempicSemaglutide | 23 | $26,552 |
| Atorvastatin Calcium | 1,144 | $19,901 |
| JanuviaSitagliptin Phosphate | 16 | $18,945 |
| TrulicityDulaglutide | 24 | $14,581 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $11,854 |
| RexultiBrexpiprazole | 16 | $11,195 |
| MyrbetriqMirabegron | 14 | $11,145 |
| Losartan Potassium | 557 | $10,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $826 | $175,854403 claims |
| Boehringer IngelheimJardiance | $202 | $82,007144 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,273 | $77,566115 claims |
| Lilly USA, LLCMounjaro, Trulicity | $526 | $64,20663 claims |
| Johnson & JohnsonXarelto | $100 | $51,67087 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $827 | $47,995125 claims |
| Novo NordiskOzempic | $921 | $26,55223 claims |
| MerckJanuvia | $55 | $18,94516 claims |
| AbbVieLinzess, Alphagan P | $1,183 | $14,58941 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $213 | $11,19516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Saint Clair Shores
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.